Erik D. Roberson MD PhD

Neurodegenerative, Dementia & Geriatrics

Rebecca Gale-Heersink Endowed Chair; Director, Alzheimer's Disease Center; Director, Killion Center for Neurodegeneration and Experimental Therapeutics

Join to View Full Profile

1717 6th Ave SBirmingham, AL 35233
Phone+1 800-822-8816
Fax+1 205-975-7365

Education & Training

University of California (San Francisco)Residency, Neurology, 2000 - 2003
Baylor College of MedicineInternship, Transitional Year, 1999 - 2000
Baylor College of MedicineClass of 1999

Certifications & Licensure

CA State Medical License 2001 - Present
AL State Medical License 2008 - 2025
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
RECRUITING
PHASE2, PHASE3
Safety Study of TPI-287 to Treat CBS and PSP Start of enrollment: 2014 May 01
Completed
Phase 1

Publications & Presentations

PubMed

Reduction of sphingomyelinase activity associated with progranulin deficiency and frontotemporal dementia.
Nicholas R Boyle, Stephanie N Fox, Aniketh S Tadepalli, Nicholas T Seyfried, Thomas Kukar
Neurobiology of Disease. 2025-09-01
Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Al...
Farid Rajabli, Penelope Benchek, Giuseppe Tosto, Nicholas Kushch, Jin Sha
Genome Biology. 2025-07-17
Author Correction: Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.
Rowan Saloner, Adam M Staffaroni, Eric B Dammer, Erik C B Johnson, Emily W Paolillo
Nature Aging. 2025-07-01

Journal Articles

Reduction of Microglial Progranulin Does Not Exacerbate Pathology or Behavioral Deficits in Neuronal Progranulin-Insufficient Mice
Erik Roberson, MD, ScienceDirect

Press Mentions

Advancing Health Through DiscoveryJuly 22nd, 2025
$10 Million Endowment to UAB Will Support Parkinson’s, Alzheimer’s, Huntington’s and ALS Research and EducationApril 14th, 2025
Heersink Office of Research Emphasizes Collaboration and Innovation at 2025 Annual Research RetreatMarch 4th, 2025
Join now to see all

Grant Support

UAB Alzheimer's Disease Research CenterUNIVERSITY OF ALABAMA AT BIRMINGHAM2024–2029
UAB Training Program in NeurodegenerationUNIVERSITY OF ALABAMA AT BIRMINGHAM2017–2027
UAB Training Program in NeurodegenerationUNIVERSITY OF ALABAMA AT BIRMINGHAM2017–2027
UAB Training Program in NeurodegenerationUNIVERSITY OF ALABAMA AT BIRMINGHAM2017–2027
Circadian changes in network excitability and Alzheimer disease pathogenesisUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2026
Circadian changes in network excitability and Alzheimer disease pathogenesisUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2026
Circadian changes in network excitability and Alzheimer disease pathogenesisUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2026
Circadian changes in network excitability and Alzheimer disease pathogenesisUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2026
Circadian changes in network excitability and Alzheimer disease pathogenesisUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2026
Circadian changes in network excitability and Alzheimer disease pathogenesisUNIVERSITY OF ALABAMA AT BIRMINGHAM2021–2026
Mechanisms For The Benefit Of TAU Reduction In Alzheimer Disease ModelsNational Institute Of Neurological Disorders And Stroke2011–2012
Mechanisms For TAU Involvement In Alzheimer'S DiseaseNational Institute Of Neurological Disorders And Stroke2008–2010
Mechanisms For TAU Involvement In Alzheimer'S DiseaseNational Institute Of Neurological Disorders And Stroke2006–2008